BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 30626401)

  • 1. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
    Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
    Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
    Duan J; Xu J; Wang Z; Bai H; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Han J; Wang D; Tian Y; Yang Z; Zhang L; Chuai S; Ye J; Zhu G; Zhao J; Wu YL; Wang J
    J Thorac Oncol; 2020 Dec; 15(12):1857-1870. PubMed ID: 32916309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
    Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
    Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Fan G; Zhang K; Ding J; Li J
    Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer.
    Chen K; Zhang J; Guan T; Yang F; Lou F; Chen W; Zhao M; Zhang J; Chen S; Wang J
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1123-1131.e2. PubMed ID: 28625771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
    Kordiak J; Szemraj J; Grabska-Kobylecka I; Bialasiewicz P; Braun M; Kordek R; Nowak D
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):241-251. PubMed ID: 30368666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.